ensysce.com (ENSC): Utang-utang marang kapitalisasi buku

The loyalty of specialized investors in Ensysce Biosciences (ENSC) is based on an ethical approach to combating the opioid crisis. The degree of balance sheet capital coverage by debt obligations clearly demonstrates asset structure management, where the value of 0.00 serves as the current metric. The company's success is driven by partnerships with drug protection institutes and the implementation of TAAP technology, which eliminates the risk of overdose in the treatment of chronic pain.

Ensysce Biosciences (ENSC) is scaling its TAAP technology to capture the safe analgesics market. This indicator determines the share of borrowed funds in the issuer's total balance sheet value of assets. Investors analyze this ratio to assess financial stability and the degree of dependence on creditors. The dynamics of the current debt level relative to balance sheet equity reveal undercapitalization risks during the execution of costly clinical trials. The stability of this metric confirms the company's ability to finance expansion without a critical debt load.